We review some of the most important clinical developments in HIV that we’ve witnessed in 2021, with an eye toward how those developments will inform and alter our response to HIV in 2022 and beyond.   Our guest: David Alain Wohl, M.D., a professor of medicine in the Division of Infectious Diseases at the University of North Carolina and the site leader of the HIV Prevention and Treatment Clinical Trials Unit at UNC Chapel Hill.   Our topics: HIV and COVID-19; long-acting antiretroviral treatment; PrEP (pre-exposure prophylaxis); and how racism impacts HIV mortality rates.   Our host: Myles Helfand, executive editor of TheBodyPro.   Relevant reading:   -- Top 10 HIV Clinical Developments of 2021: https://www.thebodypro.com/article/hiv-top-10-2021-clinical-developments    -- Cabotegravir PrEP FDA approval: https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention   -- Islatravir trials halted: https://www.aidsmap.com/news/dec-2021/trials-long-acting-islatravir-hiv-treatment-and-prevention-placed-hold   The podcast team: Alex Portaluppi and Lucy Mueller, producers; Alina Mogollon-Volk, project manager; and Maria Elena Perez, content editor.

Ver todos los episodios